Screening Dihydrofolate Reductase (DHFR) Inhibitors and Potassium Channel Blockers for HAT, Leishmaniasis, and Malaria Drug Discovery

Status
On going
Start date
Start stage
Screening
Disease
Malaria
Leishmaniasis
Human African trypanosomiasis (HAT)
Research areas
Drug

Professor Fabrice Boyom, head of the Antimicrobial & Biocontrol Agents Unit (AmBcAU) at the University of Yaounde I, is working toward the discovery and development of novel drugs against HAT, Leishmaniasis, and Malaria by targeting the parasites’ critical metabolic pathways. To support Professor Boyom’s drug discovery efforts, Eisai will share dihydrofolate reductase (DHFR) inhibitors and potassium channel blockers.